Vivani Medical (NASDAQ:VANI) Director Gregg Williams Acquires 1,737,765 Shares of Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,737,765 shares of Vivani Medical stock in a transaction on Thursday, January 15th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $1,981,052.10. Following the completion of the transaction, the director owned 26,564,109 shares of the company’s stock, valued at $30,283,084.26. This represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

• On Monday, December 15th, Gregg Williams acquired 1,737,765 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $1,981,052.10.
• On Saturday, November 15th, Gregg Williams bought 1,737,764 shares of Vivani Medical stock. The stock was acquired at an average cost of $1.14 per share, for a total transaction of $1,981,050.96.
• On Monday, October 27th, Gregg Williams purchased 3,703,703 shares of Vivani Medical stock. The shares were acquired at an average cost of $1.62 per share, with a total value of $5,999,998.86.

Vivani Medical Trading Up 7.1%

Shares of NASDAQ VANI opened at $1.36 on Wednesday. Vivani Medical, Inc. has a 12-month low of $0.91 and a 12-month high of $1.92. The company has a market cap of $99.21 million, a P/E ratio of -3.02 and a beta of 3.07. The stock has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.39.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, sell-side analysts forecast that Vivani Medical, Inc. will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP raised its stake in shares of Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after purchasing an additional 16,200 shares in the last quarter. Panagora Asset Management Inc. bought a new stake in Vivani Medical in the second quarter valued at about $25,000. Finally, Citadel Advisors LLC bought a new stake in Vivani Medical in the third quarter valued at about $26,000. 6.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Zacks Research raised shares of Vivani Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. Finally, Wall Street Zen upgraded shares of Vivani Medical to a “sell” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.